Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCT POWR Grades
- Sentiment is the dimension where ONCT ranks best; there it ranks ahead of 95.25% of US stocks.
- The strongest trend for ONCT is in Growth, which has been heading down over the past 179 days.
- ONCT's current lowest rank is in the Growth metric (where it is better than 3.61% of US stocks).
ONCT Stock Summary
- For ONCT, its debt to operating expenses ratio is greater than that reported by merely 4.89% of US equities we're observing.
- ONCT's price/sales ratio is 15.92; that's higher than the P/S ratio of 91.07% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for Oncternal Therapeutics Inc; that's greater than it is for only 6.54% of US stocks.
- Stocks that are quantitatively similar to ONCT, based on their financial statements, market capitalization, and price volatility, are SLDB, FDMT, ACET, CRBP, and CYCN.
- Visit ONCT's SEC page to see the company's official filings. To visit the company's web site, go to www.oncternal.com.
ONCT Valuation Summary
- ONCT's price/sales ratio is 58.7; this is 1444.74% higher than that of the median Healthcare stock.
- ONCT's EV/EBIT ratio has moved up 15.2 over the prior 214 months.
- ONCT's EV/EBIT ratio has moved up 15.2 over the prior 214 months.
Below are key valuation metrics over time for ONCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ONCT | 2021-08-31 | 58.7 | 2.2 | -10.8 | -5.8 |
| ONCT | 2021-08-30 | 56.5 | 2.1 | -10.4 | -5.4 |
| ONCT | 2021-08-27 | 57.1 | 2.1 | -10.6 | -5.5 |
| ONCT | 2021-08-26 | 54.9 | 2.0 | -10.1 | -5.1 |
| ONCT | 2021-08-25 | 53.5 | 2.0 | -9.9 | -4.9 |
| ONCT | 2021-08-24 | 54.8 | 2.0 | -10.1 | -5.1 |
ONCT Growth Metrics
- The 3 year price growth rate now stands at -83.86%.
- Its 3 year net cashflow from operations growth rate is now at -76.51%.
- The 2 year price growth rate now stands at -97.85%.
The table below shows ONCT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 5.347 | -23.884 | -25.817 |
| 2021-06-30 | 3.804 | -22.831 | -20.582 |
| 2021-03-31 | 3.544 | -19.444 | -18.435 |
| 2020-12-31 | 3.375 | -17.495 | -17.225 |
| 2020-12-31 | 3.375 | -17.495 | -17.225 |
| 2020-09-30 | 2.522 | -16.629 | -18.824 |
ONCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ONCT has a Quality Grade of D, ranking ahead of 14.56% of graded US stocks.
- ONCT's asset turnover comes in at 0.042 -- ranking 334th of 682 Pharmaceutical Products stocks.
- CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with ONCT.
The table below shows ONCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.042 | 1 | 6.705 |
| 2021-03-31 | 0.051 | 1 | 4.190 |
| 2020-12-31 | 0.075 | 1 | 3.387 |
| 2020-12-31 | 0.075 | 1 | 3.387 |
| 2020-09-30 | 0.123 | 1 | 3.414 |
| 2020-06-30 | 0.119 | 1 | 3.551 |
ONCT Price Target
For more insight on analysts targets of ONCT, see our ONCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.50 | Average Broker Recommendation | 1.38 (Strong Buy) |
ONCT Stock Price Chart Interactive Chart >
ONCT Price/Volume Stats
| Current price | $0.83 | 52-week high | $5.88 |
| Prev. close | $0.86 | 52-week low | $0.69 |
| Day low | $0.76 | Volume | 183,400 |
| Day high | $0.90 | Avg. volume | 458,901 |
| 50-day MA | $1.17 | Dividend yield | N/A |
| 200-day MA | $2.62 | Market Cap | 40.79M |
Oncternal Therapeutics, Inc. (ONCT) Company Bio
Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.
Latest ONCT News From Around the Web
Below are the latest news stories about Oncternal Therapeutics Inc that investors may wish to consider to help them evaluate ONCT as an investment opportunity.
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate CancerSession will include a discussion of the treatment landscape for Mantle Cell Lymphoma, including potential role of Zilovertamab, Oncternal’s ROR1 antibody ready for Phase 3 in R/R MCL, with recent FDA agreement on study designThe discussion will also cover perspectives on current and next generation treatments for patients with advanced prostate cancer, including potential role of ONCT-534, Oncternal’s novel dual action androgen receptor inhibitor (DAARI)Webinar on Tuesday, January 25th from 2:3 |
Traverso Chambers Private Wealth Management, LLC Buys WisdomTree U.S. ...Investment company Traverso Chambers Private Wealth Management, LLC (Current Portfolio) buys WisdomTree U.S. |
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Allena Pharmaceuticals (ALNA) and Gritstone Oncology (GRTS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oncternal Therapeutics (ONCT – Research Report), Allena Pharmaceuticals (ALNA – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments. Oncternal Therapeutics (ONCT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics today and set a price target of $9.00. The company's shares closed last Tuesday at $2.34. According to TipRanks. |
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell LymphomaThe company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinibThe FDA also provided positive feedback on the proposed key clinical and regulatory requirements of Oncternal’s development program for zilovertamab in MCLGlobal registrational Study ZILO-301 is expected to be initiated in the second quarter of 2022Oncternal Therapeutics will host a conference call |
H.C. Wainwright Thinks Oncternal Therapeutics’ Stock is Going to RecoverH.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics (ONCT – Research Report) today and set a price target of $9.00. The company's shares closed last Monday at $2.56, close to its 52-week low of $2.54. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.7% and a 21.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Inovio Pharmaceuticals, and Vallon Pharmaceuticals. Currently, the analyst consensus on Oncternal Therapeutics is a Moderate Buy with an average price target of $9.00. |
ONCT Price Returns
| 1-mo | -22.43% |
| 3-mo | -55.85% |
| 6-mo | -73.48% |
| 1-year | -84.63% |
| 3-year | -88.49% |
| 5-year | -97.42% |
| YTD | -63.44% |
| 2021 | -53.67% |
| 2020 | 24.05% |
| 2019 | -27.66% |
| 2018 | -93.86% |
| 2017 | 140.72% |
Loading social stream, please wait...